Semarion
Biotech · Cambridge, GB
University of Cambridge spin-out converting adherent cells into barcoded, assay-ready microcarriers (SemaCyte) for drug discovery.
Funding history
| Date | Round | Amount |
|---|
| Mar 2026 | Seed Cambridge's Semarion raised GBP 2.9M led by Parkwalk to scale its SemaCyte cell-assay platform for drug discovery. | $3.7M |
Investors
Cambridge Capital GroupCambridge Enterprise VenturesFound CapitalOxford Innovation FinanceParkwalkStart CodonThe FSE Group
Similar companies in Biotech
Explore funding flow on EquityFlow →